The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia

Transfusion and Apheresis Science

Volumn 37, Issue 1, 2007, Pages 57-62

  Banerji, Versha ^a,b   Johnston, James B ^a,b   Seftel, Matthew D ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

Author keywords

Chronic Lymphocytic Leukemia; Hematopoietic transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DISEASE SEVERITY; DNA MICROARRAY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOABLATIVE CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINE NUCLEOSIDES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 35348902566     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.04.008     Document Type: Article

References (42)

1. Seftel M.D., Zhang H., Turner D., Gibson S., Morales C., and Johnston J.B. CLL/SLL is more common than registry incidence suggests: a population-based study in Manitoba. Canada Blood 106 (2005) 1334
2. Johnston J.B. Chronic Lymphocytic Leukemia. 11th ed. Wintrobe's Clinical Hematology (2004), Williams and Wilkins, Philadelphia p. 2430-63
3. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
4. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., and Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
5. Binet J.L., Auquier A., Dighiero G., Chastang C., Piquet H., Goasquen J., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
6. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 47 (2006) 1477-1480
7. Catovsky D, Halsey J, Richards S. Sex as a prognostic factor in CLL. An analysis from MRC trials. IX IWCLL, San Diego, 22-24 March, 2002: 32a.
8. Molica S., Mauro F.R., Callea V., Gentile M., Giannarelli D., Lopez M., et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 46 (2005) 553-560
9. Byrd J.C., Stilgenbauer S., and Flinn I.W. Chronic Lymphocytic Leukemia. Hematol Am Soc Hematol Edu Prog (2004) 163-183
10. Dreger P. Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT. Ann Hematol 83 Suppl 1 (2004) S68-S70
11. Gribben J.G. Salvage therapy for CLL and the role of stem cell transplantation. Hematology (Am Soc Hematol Educ Prog) (2005) 292-298
12. Paneesha S., and Milligan D.W. Stem cell transplantation for chronic lymphocytic leukaemia. Br J Haematol 128 (2005) 145-152
13. Montserrat E. Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin North Am 18 (2004) 915-926 x
14. Milligan D.W., Fernandes S., Dasgupta R., Davies F.E., Matutes E., Fegan C.D., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 (2005) 397-404
15. Brion A.M., Kolb B., Audhuy B., Colombat B., Maisoneuve P., Foussard H., et al. Preliminary results of a prospective randomized study comparing first line conventional therapy versus high-dose therapy with autologous CD34+ purified progenitor cell support in B CLL patients with B and C Binet stages: The GOELAMS LLC98 study. Blood 106 (2005) 152
16. Esteve J., Villamor N., Colomer D., Cervantes F., Campo E., Carreras, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15 (2001) 445-451
17. Moreno C., Villamor N., Colomer D., Esteve J., Gine E., Muntanola A., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107 (2006) 4563-4569
18. Montserrat E., Moreno C., Esteve J., Urbano-Ispizua A., Gine E., and Bosch F. How I treat refractory CLL. Blood 107 (2006) 1276-1283
19. Milligan D.K., Dearden G., Matutes C., MacConkey E., Catovsky C., and High D. Incidence of Myelodysplasia and secondary leukemia in the UK MRC pilot study of autografting in chronic lymphocytic leukemia. Blood 106 (2005) 153
20. Zenz T.D., Krober P., Ritgen A., Bunjes M., Dohner D., and Stilgenbauer S. Graft versus host disease-like syndrome after autologous stem cell transplantation in CLL patients treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) high-dose regimen. Blood 106 (2005) 2928
21. Goldin L.R., Pfeiffer R.M., Li X., and Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish family-cancer database. Blood 104 (2004) 1850-1854
22. Rawstron A.C., Yuille M.R., Fuller J., Cullen M., Kennedy B., Richards S.J., et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 100 (2002) 2289-2290
23. Pavletic S., Zhou G., Sobocinski K., Doney K., DiPersio J., Feremens W., et al. Identical-twin transplants for B-cell chronic lymphocytic leukemia (B-CLL). Blood (2005) 106
24. Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051
25. Moreno C., Villamor N., Colomer D., Esteve J., Martino R., Nomdedeu J., et al. Allogeneic stem cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 15 (2005) 8-3433
26. Khouri IF, Keating M, Saliba RM, O'Brien S, Champlin RE, Bueso-Ramos C. The Efficacy of Non-Myeloablative allogeneic stem cell transplantation in ZAP-70 positive/chemo-antibody refractory patients with chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005;23:Part I of II.
27. Ritgen M., Stilgenbauer S., von Neuhoff N., Humpe A., Bruggemann M., Pott C., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (2004) 2600-2602
28. Michallet M., Michallet A.S., Le Q.H., Bandini G., Rowlings P.A., Deeg H.J., et al. Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia: a study from the EBMT and IBMT registries. Blood 102 (2003) 474
29. Toze C.L., Galal A., Barnett M.J., Shepherd J.D., Conneally E.A., Hogge D.E., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 36 (2005) 825-830
30. Doney K.C., Chauncey T., and Appelbaum F.R. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (2002) 817-823
31. Pavletic S.Z., Khouri I.F., Haagenson M., King R.J., Bierman P.J., Bishop M.R., et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J Clin Oncol 23 (2005) 5788-5794
32. Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106 (2005) 4389-4396
33. Esteve J., Bosch F., Moreno C., Rovira M., Fernanded-Aviles F., Martinez-Munoz C., et al. Prolonged response after allogeneic stem cell transplant (alloSct) for high-risk chronic lymphocytic leukemia (CLL): long-term outcome of a series from a single institution. Haematologica 90 Suppl 2 (2005) 41
34. Rondon G., Giralt S., Huh Y., Khouri I., Andersson B., Andreeff M., et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18 (1996) 669-672
35. Brown J.R., Li S., Kim H., Fiscer D.C., Cutler C., Ho V., et al. High levels of early donor chimerism and treatment responsive disease predict improved progression-free survival following non-myeloablative transplantation for advanced CLL. Blood (2005) 106
36. Sorror M.L., Maris M.B., Sandmaier B.M., Storer B.E., Stuart M.J., Hegenbart U., et al. Hematopoietic cell transplantation after non-myeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
37. Khouri I.F., Lee M.S., Saliba R.M., Andersson B., Anderlini P., Couriel D., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32 (2004) 28-35
38. Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi Deliliers G., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (2005) 1029-1033
39. Delgado J., Thomson K., Russell N., Ewing J., Stewart W., Cook G., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British society of blood and marrow transplantation study. Blood 107 (2006) 1724-1730
40. Caballero D., Garcia-Marco J.A., Martino R., Mateos V., Ribera J.M., Sarra J., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11 (2005) 7757-7763
41. Schetelig J., Thiede C., Bornhauser M., Schwerdtfeger R., Kiehl M., Beyer J., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem cell transplantation: the cooperative German transplant study group. J Clin Oncol 21 (2003) 2747-2753
42. Dreger P., Brand R., Hansz J., Milligan D., Corradini P., Finke J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17 (2003) 841-884